Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Philip J Saylor, M.D.

TitleAssistant Professor of Medicine
InstitutionMassachusetts General Hospital
DepartmentMedicine
AddressMassachusetts General Hospital
55 Fruit St
Boston MA 02114

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Lee RJ, Saylor PJ, Dror Michaelson M, Michael Rothenberg S, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013 Jun 1; 19(11):3088-94.
    View in: PubMed
  2. Saylor PJ. Prostate cancer: The androgen receptor remains front and centre. Nat Rev Clin Oncol. 2013 Feb 5; 10(3):126-8.
    View in: PubMed
  3. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S34-44.
    View in: PubMed
  4. Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 2013 Feb; 63(2):309-20.
    View in: PubMed
  5. Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD. Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2012 Nov; 53(11):1670-5.
    View in: PubMed
  6. Saylor PJ, Karoly ED, Smith MR. Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res. 2012 Jul 1; 18(13):3677-85.
    View in: PubMed
  7. Saylor PJ, Escudier B, Michaelson MD. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. Clin Genitourin Cancer. 2012 Jun; 10(2):77-83.
    View in: PubMed
  8. Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist. 2012; 17(2):212-9.
    View in: PubMed
  9. Saylor PJ, Michaelson MD. Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer? Oncologist. 2012; 17(2):288-90.
    View in: PubMed
  10. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011 Sep 20; 29(27):3705-14.
    View in: PubMed
  11. Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR. Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2011 Aug; 186(2):482-6.
    View in: PubMed
  12. Tabatabaei S, Saylor PJ, Coen J, Dahl DM. Prostate cancer imaging: what surgeons, radiation oncologists, and medical oncologists want to know. AJR Am J Roentgenol. 2011 Jun; 196(6):1263-6.
    View in: PubMed
  13. Saylor PJ. Targeted therapies: denosumab--a new option for solid tumors metastatic to bone. Nat Rev Clin Oncol. 2011 Jun; 8(6):322-4.
    View in: PubMed
  14. Saylor PJ, Keating NL, Freedland SJ, Smith MR. Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Drugs. 2011 Feb 12; 71(3):255-61.
    View in: PubMed
  15. Lee RJ, Saylor PJ, Smith MR. Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer. 2010 Dec 1; 8(1):29-36.
    View in: PubMed
  16. Saylor PJ. Re: Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy. Editorial comment. J Urol. 2010 Sep; 184(3):923; author reply 924.
    View in: PubMed
  17. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010 Jun; 183(6):2200-5.
    View in: PubMed
  18. Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone. 2011 Jan; 48(1):88-95.
    View in: PubMed
  19. Saylor PJ, Fogerty AE. Prostate-cancer-associated hypercoagulability: do we need to worry about androgen deprivation? Lancet Oncol. 2010 May; 11(5):406-7.
    View in: PubMed
  20. Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):211-23.
    View in: PubMed
  21. Saylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis. 2010 Mar; 13(1):20-7.
    View in: PubMed
  22. Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med. 2009 Nov; 24 Suppl 2:S389-94.
    View in: PubMed
  23. Saylor PJ, Smith MR. Prostate cancer: How can we improve the health of men who receive ADT? Nat Rev Urol. 2009 Oct; 6(10):529-31.
    View in: PubMed
  24. Saylor PJ, Michaelson MD. New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw. 2009 Jun; 7(6):645-56.
    View in: PubMed
  25. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009 May; 181(5):1998-2006; discussion 2007-8.
    View in: PubMed
  26. Saylor PJ, Reid TR. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol. 2007 Aug 10; 25(23):3544-6.
    View in: PubMed
  27. Saylor P, Hanna E, Adams JA. Mutations in the activation loop tyrosine of the oncoprotein v-Fps. Biochemistry. 1998 Dec 22; 37(51):17875-81.
    View in: PubMed
  28. Saylor P, Wang C, Hirai TJ, Adams JA. A second magnesium ion is critical for ATP binding in the kinase domain of the oncoprotein v-Fps. Biochemistry. 1998 Sep 8; 37(36):12624-30.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Saylor's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_